Lung Cancer Screening Market Size Forecast by Diagnosis Type 2034
The report on the global lung cancer screening market includes market size figures for 2025 and projections through 2034 with an expected CAGR. It explains key trends and factors that influence the industry’s growth over the forecast period. The study also highlights opportunities and challenges, giving stakeholders a clear picture of how the market is expected to develop and what influences demand for lung cancer screening technologies in coming years.
Market Size and Forecast
The lung cancer screening market was valued at USD 4.57 Billion in 2025 and is expected to grow to USD 5.00 Billion in 2026. It is projected to reach USD 10.36 Billion by 2034 with a CAGR of 9.53% during the forecast period. This growth is driven by increasing awareness of early lung cancer detection, improvements in screening technologies, and expanded healthcare services that support diagnostic procedures.
The lung cancer screening market report gives a comprehensive look at industry performance and what to expect in the future. It explains trends and drivers influencing this market over the forecast period. The report also highlights factors shaping demand and how adoption of screening methods is expected to grow as healthcare systems evolve.
Market Segmentation
The market is segmented based on cancer type, the type of diagnosis technology used, and the major end users. These segments help explain how different screening approaches and user settings contribute to overall market size and performance.
By Cancer Type
This segment focuses on the two main types of lung cancer screened in medical settings.
• Non-small Cell Lung Cancer (NSCLC): The more common form of lung cancer that is often targeted by screening programs due to its prevalence and potential treatment options.
• Small Cell Lung Cancer: A less common but aggressive form of lung cancer that also requires early detection for better outcomes.
By Diagnosis Type
This segment covers the technologies used to screen for lung cancer.
• Low Dose Spiral CT Scan: A diagnostic imaging technique that uses lower radiation doses to detect lung abnormalities early.
• Chest X-ray: A conventional imaging method used for lung examination, though less sensitive than CT scans.
By End User
This segment explains where lung cancer screening services are provided.
• Hospitals & Clinics: Major facilities where most lung cancer screening procedures are conducted by medical professionals.
• Diagnostic Centers: Standalone centers that offer specialized screening services, often with advanced imaging technology.
Key Players
Competition in the lung cancer screening market includes established healthcare and medical technology companies offering screening tools and related solutions.
• Koninklijke Philips N.V.: Offers diagnostic imaging equipment used in lung cancer screening and healthcare solutions.
• Siemens Healthineers AG: Provides advanced medical imaging systems that support lung health screening.
• Canon Medical Systems Corporation: Supplies imaging technologies, including CT scanners used for lung screening.
• GE Healthcare: Offers a range of diagnostic imaging systems that assist in early detection of lung cancer.
• FUJIFILM Holdings Corporation: Develops imaging and healthcare IT solutions used in cancer screening programs.
These companies are focusing on expanding their product portfolios and improving diagnostic technologies to support better lung cancer screening outcomes.
Regional Insights
The lung cancer screening market shows varied growth across regions worldwide.
• North America: Strong healthcare infrastructure, high awareness of early detection benefits, and widespread use of advanced imaging technologies support steady market growth. Screening programs and preventive health initiatives contribute to demand in this region.
• Europe: Developed healthcare systems and growing focus on early diagnosis create a supportive environment for lung cancer screening technologies. Increasing investments in healthcare infrastructure help expand screening services across hospitals and clinics.
• Asia-Pacific: Rising healthcare spending, growing awareness of lung cancer risks, and expanding diagnostic services are driving increased adoption of screening solutions. As access to healthcare improves, demand for early detection continues to rise.
• Latin America: Improving access to healthcare and diagnostic services is helping support growth in lung cancer screening. Greater emphasis on preventive care and rising awareness of cancer screening needs are contributing to market expansion.
• Middle East & Africa: Gradual improvements in healthcare infrastructure and increased focus on early disease detection are creating opportunities for lung cancer screening adoption in select markets.
Information Source: https://www.valuemarketresearch.com/report/lung-cancer-screening-market